Kamhada, a company that develops plasma-based drugs, has signed an agreement to acquire a plasma collection center

Kamhada, a company that develops plasma-based drugs, has signed an agreement to acquire a plasma collection center from Blood & Plasma Research from Texas for $ 1.6 million. The collection center specializes in collecting antibody-rich plasma for the anti-D vaccine, which is designed to prevent fetal anemia in pregnant women with Rh-negative blood.
Blood & Plasma Research's Plasma Collection Center is one of the few centers in the US approved by the US Food and Drug Administration (FDA) to supply the raw material for the production of this product. Vertical - that is, one that is involved in all stages of production.
He said Kamahda plans to significantly expand the antibody-rich plasma collection capability by investing in a center it has acquired and utilizing the center's license from the FDA to open more U.S. centers. London said the company would increase its range of enriched antibody products in the U.S. And increasing sales of the Anti-D product.